Immix Biopharma announces positive interim safety data: 100% IMX-110 treatment cycle completion in Phase 1b/2a trial

Immix Biopharma, Inc.

100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.
Historical comparators for approved soft tissue sarcoma drugs show 43-67% completion rates (Demetri et al., 2015; Schöffski et al., 2016).
IMX-110 has FDA Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma.
Immix Biopharma (NASDAQ: IMMX) is developing IMX-110 as monotherapy for soft tissue sarcoma, a $3B market targeting $6.5B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.